Amiloidosis sistémica con énfasis en amiloidosis de cadenas livianas de inmunoglobulinas

Palabras clave: amiloidosis, amiloidosis sistémica, amiloidosis AL, cadenas ligeras de inmunoglobulina, diagnóstico, tratamiento.

Resumen

La amiloidosis sistémica es una enfermedad poco común en la cual una proteína mal plegada se vuelve resistente a los procesos catabólicos del organismo, llevando a la formación de fibrillas que se depositan extracelularmente dentro de los tejidos, provocando disfunción de los órganos y muerte. La amiloidosis es un trastorno multisistémico que puede afectar el corazón, los riñones, los nervios, el hígado, los pulmones y el tracto gastrointestinal. Da como resultado una alta carga de síntomas, deterioro de la calidad de vida y una supervivencia más corta. Los tres tipos más importantes que explican el 90 % de los casos son: amiloidosis de cadenas livianas de inmunoglobulinas (AL), amiloidosis secundaria reactiva (AA) y amiloidosis por transtirretina (ATTR). Este artículo está enfocado en la amiloidosis AL, haciendo énfasis en cuándo se debe sospechar esta patología, en los hallazgos clínicos más frecuentes, cómo se confirma el diagnóstico y en las diferentes opciones de tratamiento que existen.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Kenny Mauricio Gálvez-Cárdenas, Hospital Pablo Tobón Uribe

Médico, Especialista en Medicina Interna, Especialista en Hematología, Unidad de Amiloidosis, Hospital Pablo Tobón Uribe. Medellín, Colombia.

Referencias bibliográficas

Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol 2018;19:755-773. https://doi.org/10.1038/s41580-018-0060-8.

Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641-2654. https://doi.org/10.1016/s0140-6736(15)01274-x.

Wisniowski B, McLeod DSA, Adams R, Harvey Y, Brown I, McGuire L, et al. The epidemiology of amyloidosis in Queensland, Australia. Br J Haematol 2019;186:829-836. https://doi.org/10.1111/bjh.16000.

Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc 2019;94:465-471. https://doi.org/10.1016/j.mayocp.2018.08.041.

Wechalekar AD, Gillmore JD, Foard D. 25 years of systemicamyloidosis. In: Hazenberg PB, ed. International amyloidosis symposium. Groningen: Netherland; 2012. p.

Díaz-Villanueva JF, Díaz-Molina R, García-González V. Protein folding and mechanisms of proteostasis. Int J Mol Sci 2015;16:17193-17230. https://doi.org/10.3390/ijms160817193.

Kundu D, Prerna K, Chaurasia R, Bharty MK, Dubey VK. Advances in protein misfolding, amyloidosis and its correlation with human diseases. 3 Biotech 2020;10:193. https://doi.org/10.1007/s13205-020-2166-x.

Knowles TP, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol 2014;15:384-396. https://doi.org/10.1038/nrm3810.

Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med 2021;289:268-292. https://doi.org/https://doi.org/10.1111/joim.13169.

Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program 2017;2017:1-12. https://doi.org/10.1182/asheducation-2017.1.1.

Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis: Current approaches to diagnosis and management. Hemasphere 2020;4:e454. https://doi.org/10.1097/hs9.0000000000000454.

Bou-Zerdan M, Nasr L, Khalid F, Allam S, Bouferraa Y, Batool S, et al. Systemic AL amyloidosis: current approach and future direction. Oncotarget 2023;14:384-394. https://doi.org/10.18632/oncotarget.28415.

Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010;85:232-238. https://doi.org/10.4065/mcp.2009.0547.

Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, et al. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2013;88:375-378. https://doi.org/10.1002/ajh.23413.

De la Torre A, Reece D, Crump M, Atenafu EG, Chen C, Prica A, et al. Light chain amyloidosis (AL) associated with B cell lymphoma a single center experience. Clin Lymphoma Myeloma Leuk 2021;21:e946-e959. https://doi.org/10.1016/j.clml.2021.07.003.

Berkowitz C, Dittus C. Diagnosis and management of AL amyloidosis due to B-cell non-Hodgkin lymphoma. Front Oncol 2022;12:915420. https://doi.org/10.3389/fonc.2022.915420.

van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Int J Lab Hematol 2016;38:110-122. https://doi.org/10.1111/ijlh.12504.

Milani P, Merlini G, Palladini G. Light chain amyloidosis. Mediterr J Hematol Infect Dis 2018;10:e2018022. https://doi.org/10.4084/mjhid.2018.022.

Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016;128:159-168. https://doi.org/10.1182/blood-2016-01-629790.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, et al. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv 2018;2:769-776. https://doi.org/10.1182/bloodadvances.2018016782.

Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-2530. https://doi.org/10.1182/blood-2006-03-001164.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 2018;4:38. https://doi.org/10.1038/s41572-018-0034-3.

Sikkink LA, Ramirez-Alvarado M. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis 2010;1:e98. https://doi.org/10.1038/cddis.2010.75.

Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: A systematic review. JAMA 2020;324:79-89. https://doi.org/10.1001/jama.2020.5493.

Baker KR. Light chain amyloidosis: Epidemiology, staging, and prognostication. Methodist Debakey Cardiovasc J 2022;18:27-35. https://doi.org/10.14797/mdcvj.1070.

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995. https://doi.org/10.1200/jco.2011.38.5724.

Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol 2015;168:207-218. https://doi.org/10.1111/bjh.13156.

Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, et al. Al amyloidosis. Orphanet J Rare Dis 2012;7:54. https://doi.org/10.1186/1750-1172-7-54.

Lacouture-Fierro JA, Mejía-Buriticá L, Ribero-Vargas DA. Amiloidosis AL: conceptos actuales. Med Lab 2022;26:119-139. https://doi.org/10.36384/01232576.572.

Hasib-Sidiqi M, Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. Blood Cancer J 2021;11:90. https://doi.org/10.1038/s41408-021-00483-7.

Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207. https://doi.org/10.1056/nejm199704243361702.

Gertz MA, Schonland S. Stem cell mobilization and autologous transplant for immunoglobulin light-chain amyloidosis. Hematol Oncol Clin North Am 2020;34:1133-1144. https://doi.org/10.1016/j.hoc.2020.07.007.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-3670.

Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998;101:766-769. https://doi.org/10.1046/j.1365-2141.1998.00772.x.

Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-1093. https://doi.org/10.1056/NEJMoa070484.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol 2015;33:3741-3749. https://doi.org/10.1200/jco.2015.62.4015.

Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 2013;48:557-561. https://doi.org/10.1038/bmt.2012.170.

Cordes S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012;118:6105-6109. https://doi.org/10.1002/cncr.27660.

Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369-373. https://doi.org/10.1111/j.1365-2141.2008.07327.x.

Kapoor P, Rajkumar SV. Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Nat Rev Clin Oncol 2017;14:73-74. https://doi.org/10.1038/nrclinonc.2016.221.

Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012;119:4860-4867. https://doi.org/10.1182/blood-2012-01-407791.

Lee JY, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, et al. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis. Amyloid 2014;21:261-266. https://doi.org/10.3109/13506129.2014.960560.

Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391-4394. https://doi.org/10.1182/blood-2011-11-390930.

Cibeira MT, Oriol A, Lahuerta JJ, Mateos MV, de la Rubia J, Hernández MT, et al. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol 2015;170:804-813. https://doi.org/10.1111/bjh.13500.

Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 2015;126:612-615. https://doi.org/10.1182/blood-2015-01-620302.

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood 2019;134:2271-2280. https://doi.org/10.1182/blood.2019000834.

Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-488. https://doi.org/10.1309/74r4-tb90-buwh-27jx.

Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol 2016;9:51. https://doi.org/10.1186/s13045-016-0283-0.

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:754-766. https://doi.org/10.1056/NEJMoa1606038.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319-1331. https://doi.org/10.1056/NEJMoa1607751.

Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood 2016;128:1987-1989. https://doi.org/10.1182/blood-2016-06-722496.

Kimmich C, Schönland SO, Müller-Tidow C, Dittrich T, U H. Daratumumab monotherapy in forty-eight heavily pretreated patients with advanced systemic light-chain amyloidosis. The XVIth International Symposium on Amyloidosis 2018;March 26-29.

Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia 2019;33:531-536. https://doi.org/10.1038/s41375-018-0262-2.

Food and Drug Administration (FDA). DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use. Maryland, Estados Unidos: FDA; 2020. Acceso 23 de agosto de 2023. Disponible en https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761145s002lbl.pdf.

European Medicines Agency. Summary of product characteristics. Darzalex product-information. The Netherlands: European Medicines Agency; 2020. Acceso 23 de agosto de 2020. Disponible en https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf.

CilinicaTrials.gov. A study to evaluate the efficacy and safety of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared to cybord alone in newly diagnosed systemic amyloid light-chain (AL) amyloidosis. Bethesda, Estados Unidos: National Library of Medicine; 2017-2023. Acceso 23 de agosto de 2023. Disponible en https://classic.clinicaltrials.gov/ct2/show/NCT03201965.

Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021;385:46-58. https://doi.org/10.1056/NEJMoa2028631.

Kastritis E, Sanchorawala V, Merlini G, on behalf of the ANDROMEDA study group. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. J Clin Oncol 2021;39:8003. https://doi.org/10.1200/JCO.2021.39.15_suppl.8003.

Palladini G, Milani P. Diagnosis and treatment of AL amyloidosis. Drugs 2023;83:203-216. https://doi.org/10.1007/s40265-022-01830-z.

Mallus MT, Rizzello V. Treatment of amyloidosis: present and future. Eur Heart J Suppl 2023;25:B99-b103. https://doi.org/10.1093/eurheartjsupp/suad082.

Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Campagnaro E, et al. Systemic light chain amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023;21:67-81. https://doi.org/10.6004/jnccn.2023.0001.

Cómo citar
1.
Gálvez-Cárdenas KM. Amiloidosis sistémica con énfasis en amiloidosis de cadenas livianas de inmunoglobulinas. Med. Lab. [Internet]. 21 de septiembre de 2023 [citado 20 de abril de 2024];27(4):395-409. Disponible en: https://medicinaylaboratoriocom.biteca.online/index.php/myl/article/view/690
Publicado
2023-09-21
Sección
Artículos de revisión

Métricas

Crossref Cited-by logo
QR Code

Algunos artículos similares: